Blossomhill Therapeutics, Inc. (BLSM)
13.94
-1.04
(-6.94%)
USD |
NASDAQ |
Oct 16, 16:00
14.03
+0.09
(+0.65%)
After-Hours: 20:00
Blossomhill Therapeutics Enterprise Value : 627.90M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 627.90M |
| October 15, 2026 | 660.96M |
| October 14, 2026 | 669.86M |
| October 13, 2026 | 676.85M |
| October 12, 2026 | 733.74M |
| October 09, 2026 | 740.42M |
| October 08, 2026 | 721.35M |
| October 07, 2026 | 712.77M |
| October 06, 2026 | 734.38M |
| October 05, 2026 | 818.61M |
| October 02, 2026 | 810.66M |
| October 01, 2026 | 775.70M |
| September 30, 2026 | 777.29M |
| September 29, 2026 | 864.06M |
| September 28, 2026 | 863.11M |
| September 25, 2026 | 812.57M |
| September 24, 2026 | 835.45M |
| September 23, 2026 | 894.89M |
| September 22, 2026 | 987.39M |
| September 21, 2026 | 1.037B |
| September 18, 2026 | 1.003B |
| September 17, 2026 | 1.037B |
| September 16, 2026 | 1.019B |
| September 15, 2026 | 889.49M |
| September 14, 2026 | 875.82M |
| Date | Value |
|---|---|
| September 11, 2026 | 847.85M |
| September 10, 2026 | 868.51M |
| September 09, 2026 | 884.09M |
| September 08, 2026 | 913.65M |
| September 04, 2026 | 884.40M |
| September 03, 2026 | 821.15M |
| September 02, 2026 | 800.81M |
| September 01, 2026 | 788.41M |
| August 31, 2026 | 766.48M |
| August 28, 2026 | 806.53M |
| August 27, 2026 | 814.16M |
| August 26, 2026 | 771.57M |
| August 25, 2026 | 770.30M |
| August 24, 2026 | 694.33M |
| August 21, 2026 | 705.45M |
| August 20, 2026 | 687.02M |
| August 19, 2026 | 698.78M |
| August 18, 2026 | 696.55M |
| August 17, 2026 | 705.45M |
| August 14, 2026 | 699.10M |
| August 13, 2026 | 704.50M |
| August 12, 2026 | 701.00M |
| August 11, 2026 | 709.90M |
| August 10, 2026 | 693.06M |
| August 07, 2026 | 693.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| IGC Pharma, Inc. | 25.92M |
| Cocrystal Pharma, Inc. | 13.16M |
| CNBX Pharmaceuticals, Inc. | 1.379M |
| Arvinas, Inc. | -104.56M |
| Fulcrum Therapeutics, Inc. | -35.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.76M |
| Total Expenses (Quarterly) | 23.76M |
| EPS Diluted (Quarterly) | -0.7475 |
| Earnings Yield | -15.46% |
| Normalized Earnings Yield | -15.46 |